Tongxinluo Capsule
No prior systematic review had specifically evaluated Tongxinluo in the ACS-PCI population before this study. Each Tongxinluo capsule contains 0.26 g of formulation, with dosing in trials ranging from 2 to 4 capsules three times daily. Pri…
1 sources - 5 claims
No prior systematic review had specifically evaluated Tongxinluo in the ACS-PCI population before this study. Each Tongxinluo capsule contains 0.26 g of formulation, with dosing in trials ranging from 2 to 4 capsules three times daily. Prior individual studies and a Cochrane systematic review had suggested TXL may reduce restenosis and recurrent cardiovascular events in patients with coronary heart disease after PCI. Tongxinluo capsule is a Chinese patent medicine based on traditional herbal theory, approved by China's State Food and Drug Administration in 1996 for angina pectoris and ischaemic stroke. Tongxinluo capsule is included in China's National List of Essential Medicines and is widely used for ACS patients undergoing PCI.